logo
'Health isn't shaped by genes alone - it's in the air and all around us'

'Health isn't shaped by genes alone - it's in the air and all around us'

Time of India23-05-2025
New Delhi:
India
stands at the cusp of becoming a global leader in
exposomics
research, with the potential to reshape its understanding and prevent the disease, said Dr
Kalpana Balakrishnan
, Dean of Sri Ramachandra Institute of Higher Education and Research.
Balakrishnan
, who was part of a recent forum on exposomics organised by the Johns Hopkins University in Washington DC, told PTI that India's unique blend of traditional and modern health risks makes it "a natural laboratory" for exposome science.
The term "exposome" was coined by Dr Christopher Wild in 2005. It refers to the totality of environmental exposures that individuals experience throughout their lives, from conception to death.
Unlike a genome, which is inherited and fixed, the exposome is dynamic, ever-shifting and deeply intertwined with health outcomes.
Noting that genes and genetic susceptibility alone cannot explain why people develop a chronic disease, Balakrishnan said, "Someone may not have the genetic markers for heart disease or diabetes, but still end up with them because of multiple environmental exposures experienced over a life course. That's the exposome."
While the Human Genome Project advanced genetic science within a decade, diseases affecting the cardiovascular system, endocrine disorders and mental health issues remain poorly understood through genetics alone, she explained, emphasising the need for cutting-edge tools that can capture exposures from chemical, physical, biological and psychosocial hazards and their interactions with lifestyles or living conditions.
When asked about what kind of tools and technologies are needed for exposome mapping, Balakrishnan told PTI that High Resolution Mass Spectrometry (HRMS) that can simultaneously screen thousands of chemical compounds in air, water, soil and food is one of the key technologies.
"You don't just test for what you expect - A, B, and C. You do untargeted analysis to discover D, E, F and beyond. Otherwise, you stay blind to the unknowns," she said.
For biological responses, Next Generation Sequencing (NGS) and a suite of omics platforms, including metabolomics, proteomics, and genomics, are vital.
"These help us understand how internal systems react to exposures," Balakrishnan said, noting that samples from blood, urine and other tissues provide critical biological signatures.
However, exposomics isn't confined to the laboratory. It now includes satellite-generated data for physical exposures like air pollution, urban heat islands, vegetation cover, and land-use changes.
"We can map environmental factors at high spatial resolution for entire populations," she said, adding that this is especially critical for a country like India, where environmental risks vary drastically by region and socioeconomic status.
Highlighting the complexity of exposomic data, Balakrishnan, who is also the director at World Health Organisation (WHO) Collaborating Centre for Occupational Environmental Health, mentioned that mapping it requires deep learning and AI-powered pattern recognition beyond basic statistical methods.
"These computational tools are crucial. We need them to make sense of massive, layered datasets across environmental samples, biological responses, and population demographics," Balakrishnan told PTI.
She further referred to the successful models in the North American and European exposome consortia, where patterns between pollution, green spaces, and genetic variants are predicting risks for diseases like diabetes and cardiovascular conditions.
"Imagine if we could replicate and scale that here in India," she said.
India's opportunity lies in its landscape, which includes traditional public health challenges like poor sanitation and lack of clean water. These challenges exist alongside modern hazards like ultra-processed food, air pollution and psychosocial stress.
"We're seeing exposure overload from both ends," Balakrishnan said. "That's why we need a holistic, integrative framework in the numerous ongoing cohorts in the country, and exposomics can give us that," she added.
Stressing that India cannot rely on siloed scientific approaches, she further stated that it is not just the job of medical scientists.
"We need engineers, economists, social scientists, and urban planners in the room - together with policymakers from the start," she emphasised.
Adding an international perspective, Dr
Rima Habre
, associate professor of environmental health and spatial sciences at the University of Southern California and co-director of the NIH-funded NEXUS Center for Exposome Research Coordination, said India holds immense potential for global collaborations in exposomics.
Speaking to PTI, Habre said, "I connected with Dr Balakrishnan around exposomics at a recent visit to Ahmedabad, India, where we were both invited speakers at an ICMR-NIOH conference.
"I presented our vision in the NEXUS Center, which I co-lead with Dr.
Gary Miller
and Dr.
Chirag Patel
, to link US-based and international researchers and infrastructure for a truly global exposome initiative."
She added that India's diversity of environmental and social stressors, shaped by unique regional policies and cultural practices, offers unparalleled insight into the totality of health-relevant exposures.
"Dr Balakrishnan's work in establishing large, population-based cohorts in India is foundational for exposomics," Habre said, calling for a globally connected but locally governed framework to reduce the environmental burden of disease.
Poornima Prabhakaran, Director of the Centre for Health Analytics Research and Trends (CHART), echoed the sentiments.
India's longitudinal research infrastructure provides a fertile ground to pioneer large-scale exposomics studies tailored to developing country contexts, she told PTI.
"As a global effort to scale exposomics gathers momentum, we must account for a multitude of diverse exposures across geographies and populations spanning biomarkers, environmental risk factors and 'omics'," she said.
This is in light of the recent
Exposome Moonshot Forum
hosted in Washington DC where there is already an effort across EU (EIRENE) and now US (NEXUS) and IREN to initiate this effort globally, Prabhakaran said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BJD supremo Naveen Patnaik hospitalised, condition stable
BJD supremo Naveen Patnaik hospitalised, condition stable

News18

time3 hours ago

  • News18

BJD supremo Naveen Patnaik hospitalised, condition stable

Agency: Bhubaneswar, Aug 17 (PTI) BJD chief and Leader of the Opposition in Odisha Assembly, Naveen Patnaik, was admitted to a private hospital here on Sunday due to dehydration. His health condition is stated to be stable. 'Shri Naveen Patnaik was admitted to SUM Ultimate Medicare, Bhubaneswar, at 5.15 pm today due to dehydration. His condition is stable and he is responding well to treatment," a bulletin issued by the private hospital said. The 78-year-old former chief minister had complained of uneasiness on Saturday night and some doctors had visited his residence, Naveen Niwas, party leaders said. BJD leaders had earlier said that he was admitted due to age-related ailments. view comments First Published: August 17, 2025, 19:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Smoking status must be captured in cancer trials, experts say in new study
Smoking status must be captured in cancer trials, experts say in new study

News18

time4 hours ago

  • News18

Smoking status must be captured in cancer trials, experts say in new study

New Delhi, Aug 17 (PTI) A group of experts from AIIMS Delhi, McMaster University in Canada and the International Agency for Research on Cancer (IARC) in France has stressed the need to record smoking status in cancer clinical trials, warning that continued tobacco use can reduce treatment efficacy and patient survival. In a commentary published in the Lancet Oncology this month, the seven authors, including Dr Abhishek Shankar from AIIMS Delhi, said knowledge of smoking status during therapy could influence clinical decisions. They argued that addressing barriers to tobacco-use assessment and embedding smoking cessation initiatives into oncology research protocols will improve trial outcomes, enhance therapeutic efficacy and save lives. The researchers cited the 2014 US Surgeon General's report 'The Health Consequences of Smoking — 50 Years of Progress', which for the first time concluded there was a causal link between cigarette smoking and adverse cancer-related outcomes, including higher all-cause and cancer-specific mortality. This report underscores the need to systematically capture smoking status in clinical trials, to refine estimates of efficacy of novel therapies and to better understand the impact of continued tobacco use across treatment modalities and disease sites. Since 2014, research has increasingly shown that continued tobacco use negatively impacts patients receiving surgery, radiotherapy or systemic therapies. The mechanisms by which tobacco smoke worsens outcomes remain unclear but may include tumour hypoxia, altered drug metabolism, stimulation of signalling pathways by nicotine and changes to the immune system, including reduced natural killer cells, the authors noted. 'Little is known about how best to overcome the effects of tobacco smoke, apart from cessation of tobacco use. Knowledge of smoking status during cancer therapy could potentially influence clinical decisions," the authors said in the commentary. They cited how the dose of erlotinib has to be doubled (from 150 mg to 300 mg daily) to achieve therapeutic concentrations in patients who continue smoking. 'These findings highlight a large gap in our understanding of how continued tobacco use might influence drug metabolism, therapeutic response and long-term outcomes," the experts said, adding that the issue is most pressing in low and middle-income countries with 80 per cent of tobacco users. Meta-analyses of lung, head and neck, hormone-responsive and other cancers show that quitting smoking after diagnosis results in longer survival, with early quitting offering the greatest benefits. The authors stressed that the survival advantage of quitting could even exceed the impact of the therapy under investigation. They also cautioned that failure to collect smoking data risks confounding trial results, especially if treatment groups are unbalanced for tobacco use. The commentary pointed out that the 2020 US Surgeon General's report recommended structured cessation efforts as standard cancer care, though it said more data was needed to confirm a causal link with improved survival. The authors referred to a 2020 US FDA–AACR–IASLC workshop which addressed the importance of tobacco-use assessment in oncology trials. Despite such efforts and published evidence, clinical trials still rarely incorporate robust tobacco-use assessments, they said. Absence of standardised tools and protocols for assessing tobacco use leads to inconsistencies in data collection, making it challenging to compare results across studies, authors added. They further said that some researchers and clinicians might perceive tobacco use as having minimal impact on clinical outcomes, leading to its omission from data collection. 'However, evidence strongly suggests that continued tobacco use can have a substantial adverse effect on cancer treatment efficacy and patient survival," the authors said. They also said that opportunities to intervene with current users after diagnosis have been missed, and more research is needed on mechanisms by which tobacco worsens outcomes. Collecting detailed smoking data requires time and resources, which might be limited in clinical trial settings, they pointed out. Electronic health record systems might not have integrated templates for recording smoking status information, leading to inconsistent documentation. The absence of automated prompts or referral systems can further impede the collection of accurate tobacco use data, the doctors said, adding that pharmaceutical manufacturers might perceive smoking status assessments as a threat. If smoking diminishes a drug's efficacy or exacerbates side-effects, it could negatively impact regulatory approval and market size, they added. Referring to a 2024 study by Cincirpini and colleagues, they said cessation support should ideally be provided within six months of diagnosis to observe the greatest survival benefit. With e-cigarette use rising globally, their use should also be captured in trials, though their impact is likely to be less severe than active smoking. In the past decade, many cancer centres in Canada, Australia and the US have made smoking cessation discussions standard practice at the time of patient registration, with advice and referrals offered. In 2023, the IASLC's Tobacco Control and Smoking Cessation Committee also issued a position statement declaring smoking status capture as a key standard for clinical trial design. 'Capturing smoking status in clinical trials should no longer be considered optional; it should be regarded as an essential core element of cancer research," the authors concluded. PTI PLB OZ OZ (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: August 17, 2025, 18:00 IST News agency-feeds Smoking status must be captured in cancer trials, experts say in new study Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

2 dead, more than 300 injured in Dahi Handi festivities in Mumbai, Thane
2 dead, more than 300 injured in Dahi Handi festivities in Mumbai, Thane

News18

time7 hours ago

  • News18

2 dead, more than 300 injured in Dahi Handi festivities in Mumbai, Thane

Mumbai, Aug 17 (PTI) Two people have died and more than 300 sustained injuries during the 'Dahi Handi' festival in Mumbai and neighbouring Thane city that drew large crowds of people, civic officials said on Sunday. Of the 318 persons injured in Mumbai, only 24, including a nine-year-old boy, have been hospitalised while the rest were discharged after treatment on Saturday, they said. The festival, celebrated to mark the birth of Lord Krishna, saw troupes of young men and women forming human pyramids to break dahi handis (pots of curd) suspended in the air with ropes. According to officials, the highest number of 135 people were injured during the festivities in the island city, followed by 111 and 72 in the western and eastern suburbs, respectively. Two of the injured persons, including a nine-year-old boy, are in a critical condition, they said. The boy, identified as Aryan Yadav, a resident of Tanaji Nagar, was injured during celebrations at a chawl and is undergoing treatment at a civic-run hospital in Kandivali, while Shreyas Chalke (23) has been admitted to government-run GT Hospital. Among the casualties, a 32-year-old man, identified as Jagmohan Shivkiran Chaudhari, fell to his death while tying a 'dahi handi' in Mankhurd in the northeastern part of the metropolis, and a 14-year-old boy was declared dead at a hospital in Ghatkopar on Saturday night. 'Chaudhari was tying the handi to a rope from the first-floor window grille of his house in Maharashtra Nagar when he fell. He was taken to the civic-run Shatabdi Govandi Hospital, where he was declared brought dead," an official said. Rohan Mohan Malvi, who was part of the Gaondevi Govinda Pathak, fell unconscious while sitting in a tempo at Adarsh Nagar in the Andheri area. He did not take part in the pyramid formation since he recently suffered a bout of jaundice. In the neighbouring Thane city, 22 participants were injured while attempting human pyramids, local civic body's disaster management cell chief Yasin Tadvi said. Of them, 17 were admitted to the Chhatrapati Shivaji Maharaj Hospital in Kalwa, including some who suffered head injuries, shoulder dislocations, waist and chest injuries, he said. An 18-year-old participant, who suffered a head injury, was referred to the state-run J J Hospital in Mumbai for advanced care. Some of the others injured were children in the age group of 5 to 10 years, the official said. Another five persons were admitted to the District Government Hospital in Thane, with injuries ranging from hand fractures to back pain and abrasions, Tadvi said. The festivities drew large crowds at multiple mandals in Thane, where actors Govinda, Chunky Pandey and Sunil Shetty joined the celebrations. PTI KK KRK BNM COR GK ARU view comments First Published: August 17, 2025, 15:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store